Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.

Bennett CL, Schooley B, Taylor MA, Witherspoon BJ, Godwin A, Vemula J, Ausdenmoore HC, Sartor O, Yang YT, Armitage JO, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Young T, Knopf KB, Chen B.

PLoS One. 2019 Jul 31;14(7):e0219521. doi: 10.1371/journal.pone.0219521. eCollection 2019.

2.

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL.

Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6.

3.

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL.

Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20. Review.

4.

Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.

Knopf K, Baum M, Shimp WS, Bennett CL, Faith D, Fishman ML, Hrushesky WJ.

BMJ. 2016 Dec 30;355:i6286. doi: 10.1136/bmj.i6286. No abstract available.

PMID:
28039123
5.

Generic oncology drugs: are they all safe?

Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, Georgantopoulos P, Raisch DW, Sartor O, Hermanson T, Kane RC, Hrushesky WJ, Riente JJ, Norris LB, Bobolts LR, Armitage JO, Bennett CL.

Lancet Oncol. 2016 Nov;17(11):e493-e501. doi: 10.1016/S1470-2045(16)30384-9. Review.

PMID:
27819247
6.

Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.

Bennett CL, Berger JR, Sartor O, Carson KR, Hrushesky WJ, Georgantopoulos P, Raisch DW, Norris LB, Armitage JO.

Br J Haematol. 2018 Jan;180(2):301-304. doi: 10.1111/bjh.14322. Epub 2016 Sep 21. No abstract available.

PMID:
27649938
7.

Cancer as a changed tissue's way of life (when to treat, when to watch and when to think).

Demicheli R, Quiton DF, Fornili M, Hrushesky WJ.

Future Oncol. 2016 Mar;12(5):647-57. doi: 10.2217/fon.15.336. Epub 2016 Feb 1. Review.

PMID:
26880385
8.

Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.

Bennett CL, Lai SY, Sartor O, Georgantopoulos P, Hrushesky WJ, Henke M, Armitage JO.

JAMA Oncol. 2016 Jan;2(1):134-6. doi: 10.1001/jamaoncol.2015.3940. Review. No abstract available.

PMID:
26606114
9.

Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor.

Hermanson TT, Hrushesky WJ, Knopf KB, Bennett CL.

J Oncol Pract. 2015 Sep;11(5):363-4. doi: 10.1200/JOP.2015.005397. Epub 2015 Aug 4. No abstract available.

PMID:
26243648
10.

Regulatory and clinical considerations for biosimilar oncology drugs.

Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL, Noxon V, Bobolts L, Armitage M, Bian J, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO.

Lancet Oncol. 2014 Dec;15(13):e594-e605. doi: 10.1016/S1470-2045(14)70365-1. Epub 2014 Nov 24. Review.

11.

Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.

Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS.

Curr Med Chem. 2013;20(33):4163-76. Review.

12.

Promising development from translational or perhaps anti-translational research in breast cancer.

Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Pachmann K, Vaidya JS.

Clin Transl Med. 2012 Aug 28;1(1):17. doi: 10.1186/2001-1326-1-17.

13.

Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.

Fishman ML, Kumar A, Davis S, Shimp W, Hrushesky WJ.

J Oncol Pract. 2012 May;8(3 Suppl):e14s-7s. doi: 10.1200/JOP.2012.000540.

14.

Correspondence.

Fishman M, Shimp W, Krook J, Kumar A, Hrushesky WJ.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):xxxvii. No abstract available.

PMID:
22773804
15.

Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences.

Fishman ML, Kumar A, Davis S, Shimp W, Hrushesky WJ.

Am J Manag Care. 2012 May 1;18(5):e168-72.

PMID:
22694110
16.

NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup.

Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, Baum M, Forget P, Dekock M, Pachmann K.

Breast Cancer Res Treat. 2012 Jul;134(2):881-8. doi: 10.1007/s10549-012-2094-5. Epub 2012 May 24.

PMID:
22622810
17.

The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer.

Grutsch JF, Ferrans C, Wood PA, Du-Quiton J, Quiton DF, Reynolds JL, Ansell CM, Oh EY, Daehler MA, Levin RD, Braun DP, Gupta D, Lis CG, Hrushesky WJ.

BMC Cancer. 2011 May 23;11:193. doi: 10.1186/1471-2407-11-193.

18.

Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer.

Grutsch JF, Wood PA, Du-Quiton J, Reynolds JL, Lis CG, Levin RD, Ann Daehler M, Gupta D, Quiton DF, Hrushesky WJ.

J Circadian Rhythms. 2011 May 18;9:4. doi: 10.1186/1740-3391-9-4.

19.

Sunspot dynamics are reflected in human physiology and pathophysiology.

Hrushesky WJ, Sothern RB, Du-Quiton J, Quiton DF, Rietveld W, Boon ME.

Astrobiology. 2011 Mar;11(2):93-103. doi: 10.1089/ast.2010.0574. Epub 2011 Mar 10.

20.

Circadian transcription profile of mouse breast cancer under light-dark and dark-dark conditions.

Oh EY, Yang X, Friedman A, Ansell CM, Du-Quiton J, Quiton DF, Wood PA, Hrushesky WJ.

Cancer Genomics Proteomics. 2010 Nov-Dec;7(6):311-22.

PMID:
21156964
21.

Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast.

Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ, Biganzoli E.

BMC Cancer. 2010 Nov 30;10:656. doi: 10.1186/1471-2407-10-656.

22.

Prohibitin as an oxidative stress biomarker in the eye.

Lee H, Arnouk H, Sripathi S, Chen P, Zhang R, Bartoli M, Hunt RC, Hrushesky WJ, Chung H, Lee SH, Jahng WJ.

Int J Biol Macromol. 2010 Dec 1;47(5):685-90. doi: 10.1016/j.ijbiomac.2010.08.018. Epub 2010 Sep 9.

23.

Cleavage of the retinal pigment epithelium-specific protein RPE65 under oxidative stress.

Lee H, Chung H, Arnouk H, Lamoke F, Hunt RC, Hrushesky WJ, Wood PA, Lee SH, Jahng WJ.

Int J Biol Macromol. 2010 Aug 1;47(2):104-8. doi: 10.1016/j.ijbiomac.2010.05.014. Epub 2010 May 25.

24.

Melatonin reprogrammes proteomic profile in light-exposed retina in vivo.

Zhang R, Hrushesky WJ, Wood PA, Lee SH, Hunt RC, Jahng WJ.

Int J Biol Macromol. 2010 Aug 1;47(2):255-60. doi: 10.1016/j.ijbiomac.2010.04.013. Epub 2010 Apr 29.

25.

Global breast cancer seasonality.

Oh EY, Ansell C, Nawaz H, Yang CH, Wood PA, Hrushesky WJ.

Breast Cancer Res Treat. 2010 Aug;123(1):233-43. doi: 10.1007/s10549-009-0676-7. Epub 2010 Feb 4.

PMID:
20130986
26.

Clock genes and cancer.

Wood PA, Yang X, Hrushesky WJ.

Integr Cancer Ther. 2009 Dec;8(4):303-8. doi: 10.1177/1534735409355292.

PMID:
20042409
27.

Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control.

Yang X, Wood PA, Hrushesky WJ.

J Biol Chem. 2010 Jan 29;285(5):3030-4. doi: 10.1074/jbc.M109.050237. Epub 2009 Dec 7.

28.

Circadian time-dependent tumor suppressor function of period genes.

Yang X, Wood PA, Ansell C, Hrushesky WJ.

Integr Cancer Ther. 2009 Dec;8(4):309-16. doi: 10.1177/1534735409352083. Epub 2009 Nov 18.

PMID:
19926612
29.

Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms.

Hrushesky WJ, Grutsch J, Wood P, Yang X, Oh EY, Ansell C, Kidder S, Ferrans C, Quiton DF, Reynolds J, Du-Quiton J, Levin R, Lis C, Braun D.

Integr Cancer Ther. 2009 Dec;8(4):387-97. doi: 10.1177/1534735409352086. Epub 2009 Nov 18. Review.

PMID:
19926611
30.

Circadian disruption, Per3, and human cytokine secretion.

Guess J, Burch JB, Ogoussan K, Armstead CA, Zhang H, Wagner S, Hebert JR, Wood P, Youngstedt SD, Hofseth LJ, Singh UP, Xie D, Hrushesky WJ.

Integr Cancer Ther. 2009 Dec;8(4):329-36. doi: 10.1177/1534735409352029. Epub 2009 Nov 18.

31.

The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day.

Yang X, Wood PA, Ansell CM, Quiton DF, Oh EY, Du-Quiton J, Hrushesky WJ.

Chronobiol Int. 2009 Oct;26(7):1323-39. doi: 10.3109/07420520903431301.

PMID:
19916834
32.

Imaging multidimensional therapeutically relevant circadian relationships.

Singletary J, Wood PA, Du-Quiton J, Wang S, Yang X, Vishnoi S, Hrushesky WJ.

Int J Biomed Imaging. 2009;2009:231539. doi: 10.1155/2009/231539. Epub 2009 Aug 16.

33.

Neuroprotective role of erythropoietin by antiapoptosis in the retina.

Chung H, Lee H, Lamoke F, Hrushesky WJ, Wood PA, Jahng WJ.

J Neurosci Res. 2009 Aug 1;87(10):2365-74. doi: 10.1002/jnr.22046.

34.

Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer.

Du-Quiton J, Wood PA, Burch JB, Grutsch JF, Gupta D, Tyer K, Lis CG, Levin RD, Quiton DF, Reynolds JL, Hrushesky WJ.

Psychooncology. 2010 Feb;19(2):180-9. doi: 10.1002/pon.1539.

PMID:
19199317
35.

Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer.

Retsky MW, Hrushesky WJ, Gukas ID.

BMC Cancer. 2009 Jan 8;9:7. doi: 10.1186/1471-2407-9-7.

36.

Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice.

Yang X, Wood PA, Ansell CM, Ohmori M, Oh EY, Xiong Y, Berger FG, Peña MM, Hrushesky WJ.

J Biochem. 2009 Mar;145(3):289-97. doi: 10.1093/jb/mvn167. Epub 2008 Dec 23.

PMID:
19106159
37.

Discovery of candidate genes and pathways that may help explain fertility cycle stage dependent post-resection breast cancer outcome.

Oh EY, Wood PA, Yang X, Hrushesky WJ.

Breast Cancer Res Treat. 2009 Nov;118(2):345-59. doi: 10.1007/s10549-008-0253-5.

PMID:
19051007
38.

Period 2 mutation accelerates ApcMin/+ tumorigenesis.

Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, Al-Assaad Z, Carnevale K, Berger FG, Peña MM, Hrushesky WJ.

Mol Cancer Res. 2008 Nov;6(11):1786-93. doi: 10.1158/1541-7786.MCR-08-0196.

39.

Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer.

Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID.

APMIS. 2008 Jul-Aug;116(7-8):730-41. doi: 10.1111/j.1600-0463.2008.00990.x. Review.

PMID:
18834415
40.

Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm.

Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ.

Breast Cancer Res Treat. 2009 Sep;117(2):423-31. doi: 10.1007/s10549-008-0133-z. Epub 2008 Jul 24.

PMID:
18651214
41.

The effects of surgery on tumor growth: a century of investigations.

Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID.

Ann Oncol. 2008 Nov;19(11):1821-8. doi: 10.1093/annonc/mdn386. Epub 2008 Jun 10. Review.

42.

A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.

Ramanathan RK, Bjarnason GA, Bernard SA, Desimone P, Braich T, Evars JP, Hrushesky WJ, Jolivet J.

Clin Colorectal Cancer. 2008 Mar;7(2):134-9.

PMID:
18501073
43.

Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures.

Demicheli R, Retsky MW, Hrushesky WJ, Baum M.

Nat Clin Pract Oncol. 2007 Dec;4(12):699-710. Review.

PMID:
18037874
44.

Seasonal modulation of post-resection breast cancer metastasis.

Oh EY, Wood PA, Du-Quiton J, Hrushesky WJ.

Breast Cancer Res Treat. 2008 Sep;111(2):219-28. Epub 2007 Oct 14.

PMID:
17934872
45.
46.

Racial disparities in breast cancer outcome: insights into host-tumor interactions.

Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I.

Cancer. 2007 Nov 1;110(9):1880-8. Review.

47.

Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Hrushesky WJ, Retsky M, Baum M, Demicheli R.

J Natl Cancer Inst. 2007 Jul 4;99(13):1053; author reply 1053-4. Epub 2007 Jun 27. No abstract available.

PMID:
17596578
48.

Authors respond to controversy surrounding breast cancer study.

Retsky M, Demicheli R, Hrushesky WJ.

Int J Surg. 2005;3(4):235-9. Epub 2005 Dec 12. No abstract available.

49.

Does surgery induce angiogenesis in breast cancer? Indirect evidence from relapse pattern and mammography paradox.

Retsky M, Demicheli R, Hrushesky WJ.

Int J Surg. 2005;3(3):179-87. Epub 2005 Sep 12.

Supplemental Content

Loading ...
Support Center